Drugs / tgAAC09
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00888446 | Oct 2005 → Dec 2007 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00482027 Comparator | Dec 2003 → Dec 2006 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tgAAC09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00888446 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “HIV genes enclosed within recombinant adeno-associated virus (rAAV) protein capsid” NCT00482027 ↗ |
| Route | Intramuscular | “intramuscular injection of tgAAC09” PMID 18544020 ↗ Jun 2008 |